MDVN) (“Medivation” or the “Company”) relating to the proposed buyout of Medivation by Pfizer Inc. Under the terms of …
Pfizer's big deal: Shares in Medivation (MDVN) are surging by about 20% premarket as Pfizer ... The announcement caused Syngenta stock to surge by about 11% in Europe. State-owned ChemChina announced earlier this year that it …
European and Asian stock markets slid Friday on reinforced concerns about ... whose shares slumped 4.9 percent in afternoon trading after US biotech company Medivation (NasdaqGS: MDVN - news) rejected an unsolicited $9.3 billion …
MDVN’s niche is research into other diseases for which few treatment options exist, but none of this new research is close enough to warrant owning the stock at $129 a share. Well, yipsee doodle dandy, I like your selection of Universal …
recent bid for Medivation MDVN.O. “The number one risk to medtech stock performance really is a rotation back into biotech,” Novarro said.
Biotech has been the speculative driver in this market and many names exploded higher on Thursday. These include Receptos (RCPT), Medivation (MDVN), Bluebird (BLUE), and Incyte (INCY) to mention a few. IBB broke out of a short …
has sent its shareholders on quite the ride this year. The cancer-drug company’s stock was down on its luck back in February, when the shares got caught up in a sweeping selloff in the biotech sector. The stock fell as low as $26.41 on …
The latest potential acquisition in the space involves disease therapy specialist Medivation Inc (NASDAQ:MDVN), which is now rumored to be attracting takeover interest from at least five big pharma companies. According to a Reuters report, …
The board of directors at Celgene Corporation (CELG) recommended a two-for-one stock split. The action is subject to shareholders ... and Medivation Inc. (MDVN) are examples of better-ranked stocks in the biopharma space. While …